ViroPharma is currently developing a number of RNA inhibitors for treatment of hepatitis C.
The company said that laboratory studies showed that VP-50406 effectively inhibits the RNA replication of HCV.
VP-50406 was in Phase II clinical trials in naive patients and non-responders. Now their website no longer mentions the product (
www.viropharma.com).